Cet anticorps anti-RAD51 Monoclonal Souris (Clone RAD51-2701) (ABIN7868107) détecte spécifiquement RAD51 dans WB, FACS et IHC (p).
L’anticorps est réactif avec des échantillons de Humain.
RAD51
Reactivité: Humain, Souris, Rat
WB
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
Optimal dilution of the RAD51 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Restrictions
For Research Use only
Format
Liquid
Concentration
0.2 mg/mL
Buffer
0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Stockage commentaire
Store the RAD51 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Antigène
RAD51
(DNA Repair Protein Homolog 1 (RAD51))
Autre désignation
RAD51
Sujet
RAD51 is one of the key factors of DNA repair by homologous recombination and has been shown to have anti-apoptotic activity in tumor cells. RAD51 protein interacts with a variety of tumor suppressor proteins including p53, BRCA1 and BRCA2. Elevated expression of RAD51 enhances radio-resistance of human tumor cells. Overexpression of RAD51 protein in tumor cells renders them resistant against cytotoxic drugs like Cisplatin. RAD51 interacts with BRCA1 and BRCA2 to influence subcellular localization and cellular response to DNA damage. BRCA2 inactivation may be a key event leading to genomic instability and tumorigenesis from deregulation of RAD51. High-level expression of RAD51 has been observed in a variety of human malignancies. RAD51 overexpression correlates with histological grading of the tumor in invasive ductal mammary carcinoma.